The findings could enable more efficient production of the chemotherapeutic Taxol.

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors.

A new study using one of the world’s largest cancer registries shows that patient outcomes can be significantly impacted depending on when colorectal cancer (CRC) is diagnosed related to other cancers.

In a new collaboration that could transform how cancer is treated, OCCAM Immune—a Mount Sinai initiative focused on understanding the immune system’s role in disease—is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies. Under the agreement, OCCAM Immune and CRI have established a long-term plan to support ongoing immune monitoring across CRI’s clinical trials. The collaboration provides a flexible framework for launching new projects efficiently and will focus on tracking how patients’ immune systems respond to treatment, with the goal of identifying which patients are most likely to benefit from certain immunotherapies and why.